Market overview
The global clinical nutrition market is worth USD 35.3 bn in 2026 and is forecast to reach USD 69.5 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Oral nutritional supplements is the largest by product segment.
| Scope | Medical nutrition products used under clinical supervision: enteral tube feeds, oral nutritional supplements, parenteral nutrition, specialised infant formulas and foods for special medical purposes. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 33.0 bn |
| Value 2026 | USD 35.3 bn |
| Value 2036 | USD 69.5 bn |
| CAGR 2026-2036 | 7.0% |
| Volume 2026 | 4,450 thousand tonnes |
| Volume 2036 | 7,924 thousand tonnes |
| Average price 2026 | USD 7,936 per tonne |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Clinical Nutrition market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 35.3 bn |
| 2027 | USD 37.8 bn |
| 2028 | USD 40.4 bn |
| 2029 | USD 43.3 bn |
| 2030 | USD 46.3 bn |
| 2031 | USD 49.5 bn |
| 2032 | USD 53.0 bn |
| 2033 | USD 56.7 bn |
| 2034 | USD 60.7 bn |
| 2035 | USD 64.9 bn |
| 2036 | USD 69.5 bn |
Clinical Nutrition market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral nutritional supplements | 36.0% | 34.8% | USD 12.7 bn | 6.6% |
| Enteral nutrition | 24.0% | 24.3% | USD 8.5 bn | 7.1% |
| Parenteral nutrition | 20.0% | 17.6% | USD 7.1 bn | 5.6% |
| Infant and metabolic formulas | 20.0% | 23.3% | USD 7.1 bn | 8.6% |
By patient group
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adults and elderly | 55.0% | 56.9% | USD 19.4 bn | 7.4% |
| Infants and children | 30.0% | 28.3% | USD 10.6 bn | 6.4% |
| Metabolic and rare disease | 15.0% | 14.8% | USD 5.3 bn | 6.9% |
By route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral nutrition supplements | 30.0% | 29.0% | USD 10.6 bn | 6.6% |
| Tube feeding | 26.0% | 26.0% | USD 9.2 bn | 7.0% |
| Parenteral | 44.0% | 45.0% | USD 15.5 bn | 7.2% |
By formulation
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Standard | 48.0% | 44.0% | USD 16.9 bn | 6.1% |
| Disease specific | 32.0% | 34.0% | USD 11.3 bn | 7.7% |
| Elemental | 20.0% | 22.0% | USD 7.1 bn | 8.0% |
By channel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 46.0% | 42.0% | USD 16.2 bn | 6.0% |
| Retail pharmacies | 26.0% | 24.0% | USD 9.2 bn | 6.2% |
| Home care | 20.0% | 22.0% | USD 7.1 bn | 8.0% |
| Online | 8.0% | 12.0% | USD 2.8 bn | 11.4% |
Top 25 countries for clinical nutrition by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 78.0% of 2026 revenue and the 25 countries below together hold 95.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 10.6 bn | 30.0% | USD 19.8 bn | 6.5% |
| 2 | China | USD 4.2 bn | 12.0% | USD 10.5 bn | 9.5% |
| 3 | Germany | USD 2.8 bn | 8.0% | USD 5.1 bn | 6.0% |
| 4 | Japan | USD 2.5 bn | 7.0% | USD 4.2 bn | 5.5% |
| 5 | France | USD 1.8 bn | 5.0% | USD 3.1 bn | 5.9% |
| 6 | United Kingdom | USD 1.4 bn | 4.0% | USD 2.6 bn | 6.5% |
| 7 | Italy | USD 1.2 bn | 3.5% | USD 2.2 bn | 6.0% |
| 8 | Spain | USD 1.1 bn | 3.0% | USD 2.0 bn | 6.6% |
| 9 | Brazil | USD 1.1 bn | 3.0% | USD 2.3 bn | 8.0% |
| 10 | India | USD 883 mn | 2.5% | USD 2.5 bn | 11.0% |
| 11 | South Korea | USD 854 mn | 2.4% | USD 1.8 bn | 7.7% |
| 12 | Russia | USD 854 mn | 2.4% | USD 1.8 bn | 7.7% |
| 13 | Netherlands | USD 727 mn | 2.1% | USD 1.3 bn | 6.4% |
| 14 | Australia | USD 572 mn | 1.6% | USD 1.1 bn | 6.4% |
| 15 | Canada | USD 501 mn | 1.4% | USD 924 mn | 6.3% |
| 16 | Switzerland | USD 491 mn | 1.4% | USD 910 mn | 6.4% |
| 17 | Mexico | USD 395 mn | 1.1% | USD 827 mn | 7.7% |
| 18 | Turkey | USD 371 mn | 1.1% | USD 771 mn | 7.6% |
| 19 | Taiwan | USD 293 mn | 0.8% | USD 611 mn | 7.6% |
| 20 | Thailand | USD 237 mn | 0.7% | USD 493 mn | 7.6% |
| 21 | Belgium | USD 233 mn | 0.7% | USD 431 mn | 6.3% |
| 22 | Poland | USD 219 mn | 0.6% | USD 451 mn | 7.5% |
| 23 | Austria | USD 187 mn | 0.5% | USD 347 mn | 6.4% |
| 24 | Saudi Arabia | USD 162 mn | 0.5% | USD 333 mn | 7.5% |
| 25 | Indonesia | USD 120 mn | 0.3% | USD 250 mn | 7.6% |
| Rest of world | USD 1.6 bn | 4.4% | USD 2.7 bn | 5.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Nestle Health Science
- Abbott
- Danone (Nutricia)
- Fresenius Kabi
- Baxter
- B. Braun
Group 2: Regional and specialist players
- Reckitt (Mead Johnson)
- Hormel Health Labs
- Ajinomoto
- Meiji
- Otsuka Pharmaceutical
- Morinaga Milk
- FrieslandCampina
- Nualtra
Group 3: Emerging and niche players
- Kate Farms
- Medtrition
- Real Food Blends
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the clinical nutrition market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.
The market is divided by product, by patient group, by route, by formulation, by channel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the clinical nutrition market?
The global clinical nutrition market is estimated at USD 33.0 bn in 2025 and USD 35.3 bn in 2026.
How fast will the clinical nutrition market grow?
It is forecast to reach USD 69.5 bn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 34.2 bn.
Which country is the largest market for clinical nutrition?
United States is the largest market by revenue at USD 10.6 bn in 2026, 30.0% of the global total. The three largest countries together hold 50.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 11.0% a year from 2026 to 2036.
Which clinical nutrition segment is largest?
In the by product split, Oral nutritional supplements is the largest segment with 36.0% of 2026 revenue.
Who are the leading clinical nutrition companies?
Global leaders include Nestle Health Science, Abbott, Danone (Nutricia), Fresenius Kabi.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Nasal SprayUSD 35.0 bn · 5.5% CAGR
- Obesity DrugsUSD 33.3 bn · 14.0% CAGR
- BiosimilarsUSD 37.8 bn · 15.0% CAGR
- Diabetes CareUSD 32.7 bn · 9.0% CAGR
- Molecular DiagnosticsUSD 32.4 bn · 8.0% CAGR
- Regenerative MedicineUSD 31.6 bn · 13.0% CAGR
- Inhalation Drug DeliveryUSD 40.1 bn · 5.5% CAGR
- Medical TourismUSD 40.3 bn · 12.0% CAGR